Razvan Cristescu

11PUBLICATIONS
85CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Jun 10, 2024
Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer.

Min-Hyun Baek, Lei Chen, Cumhur Tekin

|Jun 01, 2024
Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.

Thomas Powles, Yen-Hwa Chang, Yoshiaki Yamamoto

|Jul 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.

Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann

|Jun 03, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.

Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang

|Mar 05, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

Joaquim Bellmunt, Ronald de Wit, Yves Fradet

Pageof 2

Frequent Collaborators

4 joint publications

Andrey Loboda

3 joint publications

Thomas Powles

2 joint publications

Yves Fradet

2 joint publications

Xiao Qiao Liu